1）参与完成化学药品一类抗肿瘤药物——安替安吉肽的临床前研究，并获得药物临床试验批件，批件号：2013L01914；

2）参与完成化学药品一类抗类风湿药物——派格安替安吉肽的临床前研究，并获得药物临床试验批件，批件号：2018L02321；

3）主持中国博士后科学基金面上项目，2017M621884，长链非编码RNA HOTTIP促进食管鳞癌转移的机制研究；

4）作为主要骨干人员参与国家“重大新药创制”科技重大专项：一类抗类风湿新药派格安替安吉肽的临床试验研究及关键技术开发，课题编号：2019ZX09301124。

1）Wang Y, Li M, Xu H*, et al. Natural killer cell-derived exosomal miR-1249-3p attenuates insulin resistance and inflammation in mouse models of type 2 diabetes, Signal Transduct Target Ther, 2021, 6(1): 409. (IF=38.104)

2）Wang Y, Lu J, Xu H*, et al. Tumor-derived EV-encapsulated miR-181b-5p induces angiogenesis to foster tumorigenesis and metastasis of ESCC, Molecular Therapy - Nucleic Acids, 2020, 20: 421-437. (IF=10.183)

3）Wang Y, Li D, Xu H*, et al. Long noncoding RNA TTN-AS1 facilitates tumorigenesis and metastasis by maintaining TTN expression in skin cutaneous melanoma, Cell Death and Disease, 2020, 11(8): 664. (IF=9.685)

4）Yang P, Wang Y, Xu H*, et al. Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide, Journal of the American Chemical Society. 2020, 142(44): 18874-18885. (IF=16.383，共一作者)

5）Li M, Wang Y, Xu H*, et al. Integrins as attractive targets for cancer therapeutics, Acta Pharmaceutica Sinica B, 2021, 11(9): 2726-2737. (IF=14.903，共一作者)

6）Lin C, Wang Y, Guo C, Xu H*, et al. Transcriptional and posttranscriptional regulation of HOXA13 by lncRNA HOTTIP facilitates tumorigenesis and metastasis in esophageal squamous carcinoma cells, Oncogene, 2017, 36(38): 5392-5406. (IF=8.756，共一作者)

7）Li D, Wang Y, Xu H*, Hu J*, et al. NK cell-derived exosomes carry miR-207 and alleviate depression-like symptoms in mice, Journal of Neuroinflammation, 2020, 17(1): 126. (IF=9.587，共一作者)

8）Li D, Wang Y, Xu H*, Hu J*, et al. CD200-CD200R1 signalling attenuates imiquimod-induced psoriatic inflammation by inhibiting the activation of skin inflammatory macrophages, International Immunopharmacology, 2020, 78: 106046. (IF=5.714，共一作者)

9）Xia C, Wang Y, Xu H*, et al. Novel Peptide CM 7 Targeted c-Met with Antitumor Activity, Molecules, 2020, 25(3): 451-470. (IF=4.927，共一作者)

10）Wang X, Wang Y, Hu J*, Xu H*. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity, Cancer Medicine, 2021, 10(6): 2125-2136. (IF=4.711，共一作者)